| Protocol No. | Title |
| 08271 | The TrialNet Natural History Study of the Development of Type 1 Diabetes |
| 140074 | Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry |
| 2006NT007 | Diagnostic Prostate Magnetic Resonance Imaging at 3 Tesla with an Endorectal Coil |
| 2007NT080 | Magnetic Resonance Imaging of the Prostate at 7 Tesla |
| 2009UC147-2 | I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2 |
| 2011NTLS157 | Use of Pap test samples to study human diseases |
| 2013LS104 | MT2013-31:Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis following Conditioning with Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG |
| 2013NTUC039 | MT2013-19R: BMT Long-Term Follow-up Study -2 |
| 2014NTLS069 | Personalized mouse models of chemotherapy resistance in ovarian cancer
|
| 2014NTLS071 | Family-based studies of susceptibility to early onset disease |
| 2015NTLS174 | MT2013-02: Establishment of a Cell and Tissue Repository for Human Cell Reprogramming and Derivation of iPS Cell Lines to Investigate Mechanisms and Treatment of Human Disease |
| 2016LS132 | MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL) |
| 2016LS161D | MT2017-17: Alpha/Beta T Cell Depleted (alpha/beta TCD)
Hematopoietic Cell Transplantation in Patients with Inherited Bone Marrow Failure (BMF) Disorders |
| 2016NTLS035-LCNS | Solid Tumor Cancer Specimen Bank - Lung Cancer Never Smoker |
| 2016NTLS083 | Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma |
| 2016NTLS151 | Cytomegalovirus Status and Adaptive Natural Killer Cells in Ovarian Cancer: A Pilot Study |
| 2016NTLS163 | Development Of A Clinical Precision Medicine Program In Ovarian Cancer As A Paradigm For 21st Century Tailored-Health Care Solutions |
| 2017CG139 | COG AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) |
| 2017LS006 | HM2017-24 : Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM-027 |
| 2017NTLS106 | Attitudes, Perceptions and Psychosocial Determinants of Cancer Screening among East African Communities |
| 2018CG089 | COG AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
| 2018CG118 | COG AGCT1532 - A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors |
| 2018NTLS045 | MT2018-05R Clinical Outcomes in Hematopoietic Cell Transplantation or Cell Therapy |
| 2018NTLS123 | Characterization of Coagulation plus Cell Activation and Adhesion in Myeloproliferative Neoplasms |
| 2018NTLS135 | Observational Study of Exposure to Environmental Toxicants Among Firefighters |
| 2018NTUC068 | Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL)
Short Title: AYA ALL |
| 2019CG218 | COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
| 2019LS010 | A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) or Placebo in Combination with Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Treatment Naïve Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer |
| 2019NTCG190 | MT2019-38: Development and Psychometric Testing of a Pediatric Chronic Graft-Versus-Host Disease (GVHD) Symptom Scale (PCSS) |
| 2019NTLS027 | MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank |
| 2019NTLS030 | The role of cytomegalovirus and inflammation on patient symptoms and outcomes in ovarian cancer |
| 2019NTLS034 | MT2018-17:DNA adductomics for the identification of DNA adducts to be used as biomarkers for personalized chemotherapeutic regimens |
| 2019NTLS052 | Sample Collection for Environmental Exposure |
| 2019NTLS126 | GLNE 007 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas |
| 2019NTLS211 | Understanding the impact of Female Genital Mutilation on Anorectal and Willingness to Undergo Colorectal Cancer Screening Amongst Somali Migrants to the US |
| 2019NTLS213 | Skin Cancer Risk in Patients with Autoimmune Connective Tissue Disease Treated with lmmunosuppressive Medications: a retrospective cohort study |
| 2019UC046 | MT2019-09: A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR alpha beta +/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol |
| 2020CG007 | COG ACNS1831 - A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) |
| 2020CG051 | COG ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) |
| 2020CG131 | MT2020-35 - COG AAML1831 - A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations |
| 2020CG187 | COG AREN1921 - Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) |
| 2020IS054 | MT2020-08 A Phase 1/1b Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191(azercabtagene zapreleucel or azer-cel), in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) |
| 2020IS117 | A Multicenter Observational Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms |
| 2020IS238 | A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors. |
| 2020LS048 | Peripheral neuropathy, neural density, and chemotherapy; a prospective cohort trial |
| 2020LS098 | MT2020-28: Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study |
| 2020LS100 | MT2020-27: Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphomas |
| 2020LS110 | Feasibility of conducting a pilot telehealth study assessing the removal
of filter ventilation on smoking behavior and biomarkers in menthol smokers switched to non-menthol cigarettes |
| 2020LS159 | Mujeres Avanzando a la Sobrevida (Women Going Forward in Survival): a Prospective Breast Cancer Cohort Study in Honduras |
| 2020UC077 | National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 |
| 2020UC141 | Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone metastases from Multiple Myeloma |
| 2021CG040 | A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCk) |
| 2021CG156 | PEPN2011 - A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors |
| 2021CG176 | A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) |
| 2021IS114 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumours |
| 2021IS148 | HM2021-31: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| 2021IS164 | Feasibility Study of Resection and GammaTile® Followed by Concomitant External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ in Newly Diagnosed Glioblastoma (GBM). |
| 2021IS173 | A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants with Advanced Cancer |
| 2021IS174 | A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Protocol Number: CA224069 |
| 2021LS034 | Telehealth study assessing the removal of filter ventilation on smoking behavior and biomarkers |
| 2021LS041 | Development of Protein Biomarkers from Urine of Prostate Cancer Patients |
| 2021LS061 | MT2021-08: Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults with Hematological Malignancies |
| 2021LS099 | Increasing HPV vaccination coverage among pediatric, adolescent, and young adult (PAYA) cancer survivors: A multilevel intervention |
| 2021LS140 | Phase I Clinical Trial of Cell Based Therapy for Duchenne Muscular Dystrophy |
| 2021LS162 | The effects of cigarette smoking and alcohol on DNA damage in the oral cavity |
| 2021UC056 | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive |
| 2022CG008 | PEPN2111 - A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma |
| 2022CG021 | COG APAL2020SC - Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies for Relapsed Leukemias |
| 2022CG090 | AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma |
| 2022CG116 | NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
| 2022CG118 | PEPN2121 : A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
| 2022CG158 | PEPN22P1: Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods |
| 2022CG166 | COG ACNS1931 - A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| 2022IS066 | A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, or with the mTOR inhibitor
Everolimus in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer |
| 2022IS096 | MT2022-41: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease and Severe Vaso-Occlusive Crises (BEACON Trial) |
| 2022IS180 | MT2024-08: Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors. |
| 2022LS030 | A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma |
| 2022LS040 | A Window of Opportunity Trial of Mirdametinib plus Vorinostat for NF1 Associated, Malignant Peripheral Nerve Sheath Tumor; MPNST |
| 2022LS100 | Time toxicity of cancer: the time demands of cancer-related activities and their impact on well-being and quality of life |
| 2022LS146 | MT2022-52: Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) with Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases |
| 2022LS170 | Project SHINE (Sleep Health INitiative for Equity): Culturally informing a sleep extension intervention for African American adults |
| 2022LS174 | MT2022-60: A phase II study of Pembrolizumab+ BEAM conditioning regimen before autologous stem cell transplant (ASCT) followed by pembrolizumab maintenance in patients of relapsed classic Hodgkin lymphoma |
| 2022LS182 | Application of Engineered Tumor Infiltrating Lymphocytes (TILs) in Pediatric Osteosarcoma |
| 2022UC044 | ITCC-101/APAL2020D - A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML (A subtrial of the PedAL/EuPAL relapsed acute leukemia master protocol) |
| 2022UC072 | MT2022-35: Black Box- Hematopoietic Stem Cell Transplant Complications |
| 2022UC108 | A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer |
| 2022UC123 | MT2022-44 Analysis of Autoinflammation in Chronic Granulomatous Disease Patients Undergoing Hematopoietic Cell Transplantation or Gene Therapy (PIDTC 6908) |
| 2022UC124 | MT2022-45 Primary Immune Regulatory Disorders (PIRD): Longitudinal Study of Clinical Presentation, Treatment and Outcomes |
| 2022UC137 | PRE-I-SPY TRIAL - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis: A Phase I/Ib platform trial |
| 2023CG022 | COG ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma |
| 2023CG042 | Quality of Life and Impact of Disease in People with Sickle Cell Disease Over Time |
| 2023CG058 | A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) |
| 2023CG071 | A Phase 1B and randomized phase 2 trial of megestrol acetate with or without ipatasertib in recurrent or metastatic endometrioid endometrial cancer |
| 2023CG077 | AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma |
| 2023CG091 | OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy |
| 2023CG093 | ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis |
| 2023CG096 | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum |
| 2023CG127 | MT2023-33 A Phase II Study of Reduced Dose Post Transplantation; Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation |
| 2023CG156 | A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) |
| 2023CG195 | COG AALL2121: A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia |
| 2023EX070 | MT2023-12: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma |
| 2023IS004 | A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer |
| 2023IS006 | Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumors |
| 2023IS006-T2 | MT2023-28: A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex,
Autologous Customized T Cell Receptor-Engineered T Cells Targeting
Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally
Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T(TM) |
| 2023IS017 | MT2023-34 A Safety and Effectiveness Registry Study of Patients with B-Thalassemia Treated with Betibeglogene Autotemcel |
| 2023IS027 | MT2023-06: A CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LERIGLITAZONE IN ADULT MALE SUBJECTS WITH CEREBRAL ADRENOLEUKODYSTROPHY |
| 2023IS037 | Phase 1, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients with Refractory Locally Advanced or Metastatic Solid Tumors |
| 2023IS068 | An International, Phase 3, Randomized, Multicenter, Open label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT) |
| 2023IS084 | HM2024-11: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLATUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA |
| 2023IS085 | A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) |
| 2023IS087 | HM2023-21: A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
|
| 2023IS104 | MT2023-22: Phase 1/2 Study of IDP-023 as a Single Agent and in Combination with Antibody Therapies in Patients with Advanced Hematologic Cancers |
| 2023IS107 | MT2023-30: A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors |
| 2023IS110 | Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1) |
| 2023IS134 | A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
| 2023IS140 | MT2023-29: Long-term Follow-up of Subjects With Sickle Cell Disease Treated With ExVivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector |
| 2023IS178 | MT2023-42: A Phase 1 Study of FT819 in B-Cell Mediated Autoimmune DIseases |
| 2023IS180 | MT2023-51 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer |
| 2023IS187 | A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003) |
| 2023IS200 | A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
|
| 2023IS205 | MT2024-05: A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 cell infusion in subjects with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT) |
| 2023LS024 | MT2023-05: GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) |
| 2023LS072 | MT2023-14: Supporting patients and caregivers during hematopoietic stem cell transplant (HSCT): What is working, not working and how can we improve? |
| 2023LS079 | Characterization of Genetically Engineered Tumor Infiltrating Lymphocytes (TIL) in Adults
Living with Sarcomas |
| 2023LS102 | Effects of relighting on smoke toxicant deliveries and subjective smoking measures |
| 2023LS109 | MT2023-24:The Minnesota Biorepository Protocol for biological samples obtained after Chimeric Antigen Receptor (CAR)-T Cell Therapy |
| 2023LS145 | Defining the Immune Landscape of Osteosarcoma at the Single-Cell Level |
| 2023LS160 | MT2023-38 Monitoring of Immune Reconstitution in Hematopoietic Cell Transplantation (HCT) and Novel Immunotherapies |
| 2023LS176 | COLLABS: Colorectal Cancer Legal and Administrative Burden Support: A Pilot Clinical Trial |
| 2023LS181 | Effects of tobacco and nicotine cessation on biomarkers |
| 2023LS185 | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
| 2023LS185R | Retreatment on "Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer" Protocol 2023LS185 / MT2023-44 |
| 2023LS215 | Development of Tobacco Related Biomarkers |
| 2023UC051 | Surgical Window of Opportunity Study of Megestrol Acetate Compared with Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia |
| 2024CG068 | ANBL2131/MT2024-35- A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma |
| 2024CG120 | PEPN2312; A Phase 1 study of GRN163L (Imetelstat, IND# 170891, NSC# 754228) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia that is in second or greater relapse or that is refractory to relapse therapy; myelodysplastic syndrome or juvenile myelomonocytic leukemia in first or greater relapse or is refractory to relapse therapy |
| 2024EX045 | MT2024-10: Expanded Access Single Patient Use of Brexucabtagene Autoleucel (Tecartus) OOS for a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia |
| 2024IS018D | MT2024-06D: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation |
| 2024IS036 | A Phase 1B/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXD) in subjects with recurrent or metastatic solid tumors (IDeate-Pantumor02) |
| 2024IS051 | MT2024-12: A Phase 1 Study Evaluating BAFFR-targeting CAR T cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) |
| 2024IS055 | HM2024-18 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis |
| 2024IS058 | A Phase 1B/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), A B7- H3 Antibody-Drug Conjugate (ADC), In combination with Atezolizumab with or Without Carboplatin as First Line Induction or Maintenance, In Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03) |
| 2024IS070 | A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, as monotherapy and in combination in participants with advanced solid tumors |
| 2024IS074 | A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy
of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy |
| 2024IS089 | A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma |
| 2024IS104 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan
Versus Treatment of Physician's Choice in Participants With
Endometrial Cancer Who Have Received Prior Platinum-based
Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy |
| 2024IS116 | A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors |
| 2024IS162 | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| 2024IS171 | MT2024-33 A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS |
| 2024IS209 | A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) |
| 2024LS022 | Assessing recall, minimum clinically important difference, and non-inferiority margin of healthcare contact days among people with cancer |
| 2024LS030 | A pilot study to evaluate the feasibility and utilization of a mobile-friendly online Survivor Care Plan (SCP). |
| 2024LS053 | Barriers to access and costs of cannabis among those recently diagnosed with cancer: Implications for recent cannabis legislation in Minnesota |
| 2024LS054 | Development of a RET-Specific Proteomic Assay from Circulating Tumor Cells in Lethal Prostate Cancer |
| 2024LS060 | A pilot study of an educational workshop for breast cancer medical professionals to increase sexual health screening in young adult breast cancer patients |
| 2024LS083 | Evaluation of patient-reported outcomes (PRO) for participants treated with GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE) |
| 2024LS126 | Randomized Clinical Trial of Culturally Aligned Digital Smoking Cessation Resources for American Indian Persons |
| 2024LS134 | Clarke Pilot CRTI; Impact of discrimination/social isolation on cardiovascular health in breast cancer survivors treated with aromatase inhibitors: link to gut microbiome |
| 2024LS138 | MT2024-24: A Pilot Study To Determine Risk Factors for Developing Financial Toxicity in Patients with Hematologic Malignancies Receiving CAR T-Cell Therapy |
| 2024LS140 | MT2024-25: Allogeneic Hematopoietic Stem Cell Transplant for Patients with High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders |
| 2024LS151 | HM2024-28: A Pilot Study to Investigate the Clinical Utility of Tremoflo Airway Oscillometry in the Pediatric and Adolescent Population with Pulmonary Pathology or at Risk of Lung Injury |
| 2024LS187 | Assessing and Enhancing Survivorship Care in Adolescent and Young Adult Cancer Survivors |
| 2024LS196 | Feasibility of saliva and remote monitoring of active CMV infection and symptoms during ovarian cancer treatment |
| 2024UC076 | A Phase 2 Randomized Trial of Neoadjuvant Enoblituzumab versus Standard of Care in Men with High-Risk Localized Prostate Cancer: The Help Elucidate & Attack Longitudinally (HEAT) Prostate Cancer Randomized Study |
| 2024UC145 | Clinical Characteristics and Factors Influencing Outcomes of Diffuse Hemispheric Glioma, H3 G34-mutant: A Multi-Institutional Retrospective Cohort Study |
| 2024UC180 | National Liver Cancer Screening Trial |
| 2024UC210 | "Engraft - A Transplant and Cellular Therapy Learning Network (ENGRAFT)
to Improve Outcomes in Stem Cell Transplant and Cellular Therapy Patients
Through Quality Improvement" |
| 2025CG018 | ALTE2131, An NCORP Phase 3 Study of Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
|
| 80802 | CALGB 80802: PHASE III RANDOMIZED STUDY OF SORAFENIB PLUS DOXORUBICIN VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) |
| ANES-2022-31352 | Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients |
| ANES-2022-31377 | To Investigate Airway Oxygen Concentrations during Rigid Bronchoscopy Procedures Performed with High Frequency Jet Ventilation |
| ANES-2023-31691 | Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery |
| ANES-2023-31918 | Rectus sheath block with liposomal bupivacaine versus thoracic epidural analgesia for pain control following pancreatoduodenectomy: a prospective, randomized, non-inferiority trial |
| ANES-2023-32053 | Addition of a pectoserratus block to interscalene block in patients undergoing total shoulder replacement. |
| ANES-2024-33184 | Effects of Pain on Laboratory Drinking Topography and Daily Drinking in People with Chronic Temporomandibular Disorder (TMD) Pain |
| CBS-2024-33212 | GC-PRO Intervention |
| CMRR-2023-32199 | CMRR Healthy Participant Registry |
| CMRR-2024-32922 | Natural History of and Genetic Modifiers in Spinocerebellar Ataxias |
| CV-2014-20799 | National Biological Sample and Data Repository for Pulmonary Arterial Hypertension |
| CV-2014-22223 | Minnesota Pulmonary Hypertension Repository Study |
| CV-2014-22442 | Cardiac Sarcoidosis Consortium |
| CV-2017-25423 | Pulmonary Hypertension Association Registry (PHAR) |
| CV-2019-27489 | Prediction Modeling in Heart Failure Patients |
| CV-2019-28111 | Patterns of Cardiovascular Disease: Characteristics, Predictors and Outcomes |
| CV-2019-28423 | The predictive value of preoperative CPX in Left Ventricular Assist Device and Orthotopic Heart Transplant outcomes |
| CV-2020-28665 | Long Term Outcomes and Quality of Life in Patients with Out of Hospital Cardiac Arrest |
| CV-2022-30951 | JIT -- Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation support During Cardiogenic Shock |
| CV-2022-31437 | Oxidative Stress Markers in Heart Failure II |
| CV-2022-31523 | Immunologic Basis of Cardiovascular Disease after COVID-19 |
| CV-2022-31579 | Physical Rehabilitation for Older Patients with Acute Heart Failure with Preserved
Ejection Fraction (REHAB-HFpEF) |
| CV-2023-32230 | Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure |
| CV-2023-32312 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled
Study of Levosimendan in Pulmonary Hypertension Patients
With Heart Failure With Preserved Left Ventricular Ejection
Fraction (PH-HFpEF); LEVEL: LEVosimendan to Improve
Exercise Limitation in Patients With PH-HFpEF |
| CV-2024-32928 | Testing the feasibility of a clinic-based assessment of exercise-induced maximum heart rate and heart rate recovery in adults without cardiovascular disease |
| CV-2024-33094 | REFORM-HF.
REducing Fluid Overload using Renal Independent systeM in Heart Failure Patients |
| DEM-2023-31500 | Senolytics To slOw Progression of Sepsis |
| DENT-2020-29282 | Brain Connectivity Patterns in Chronic Temporomandibular Joint Disorders |
| DENT-2022-31055 | Co-morbid Trigeminal Neuralgia and TMD |
| DENT-2022-31080 | Identification of biomarkers in chronic TMD patients |
| DENT-2023-31099 | Pharmacogenomic Testing to Inform Analgesic Selection for Dental-related Acute Pain Management: An Application of Precision Medicine Methods in Dentistry |
| DERM-2019-26638 | Transition of Care in Patients with Epidermolysis Bullosa: Survey Study |
| DERM-2020-28674 | Hidradenitis Suppurativa Registry |
| DERM-2020-28745 | Protocol Number: TARGET-DERM;A 5-year Longitudinal Observation Therapy for Immune-Mediated;Inflammatory Skin Conditions |
| DERM-2021-27916 | Use of Continuous Wave Doppler to assess Vascular Malformations in Pediatric Dermatology |
| DERM-2021-29370 | Measuring Alopecia Areata Patient-Reported Psychosocial Outcomes: Scale Development and Validation Part B |
| DERM-2021-30229 | Posterior lamella reconstruction by periosteal flap: a retrospective study |
| DERM-2022-31248 | Neptunia A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care |
| DERM-2022-31369 | Global Prevalence of Hidradenitis Suppurativa |
| DERM-2022-31562 | MTT for H.S. Investigate whether restoring normal gut microbiome composition with cMTT influences the relative overabundance of anaerobic bacteria and microbial diversity of the skin in patients with HS |
| DERM-2023-31404 | Analysis of Peripheral Nerve Function in Patients with Frontal Fibrosing Alopecia |
| DERM-2023-31719 | Bullying in Pediatric Alopecia Areata: A Survey Study |
| DERM-2023-31787 | H.S. Registry Analysis |
| DERM-2023-31959 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years& Less than 18 Years of Age with Alopecia Areata |
| DERM-2023-32014 | Testing Of Alternatives For Dark Hair Dyes In Patients With Proven Sensitization To Para-Phenylenediamine |
| DERM-2023-32083 | Objective validation of drug allergies- Evaluation of results from comprehensive testing in a novel drug allergy clinic |
| DERM-2023-32448 | INCB 54707-312
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa
Long-Term Extension Study (STOP-HS LTE)
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and
Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa |
| DERM-2023-32566 | MT2024-16: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Hidradenitis Suppurativa |
| DERM-2024-32369 | Coach Sun Safety Education in Youth Sports Camps |
| DMED-2024-33328 | Perceptions and Expressions of Depression and Anxiety among Indigenous Women of the Rural Peruvian Amazon |
| DMED-2025-33627 | The Sexual Pleasure and Vulnerability Project |
| ENT-2020-28903 | Vibrotactile stimulation of the larynx to treat unexplained chronic cough |
| ENT-2021-29988 | Characterization of spleen motion and anatomy using imaging and sensors |
| ENT-2022-30531 | Measurement of Upper Aerodigestive Tract Pressures During Phonation |
| ENT-2022-30785 | UAZ21-07-01 Metformin Study |
| ENT-2022-31139 | PIOGLITAZONE-METFORMIN COMBINATION TREATMENT FOR HIGH RISK ORAL PRENEOPLASIA |
| ENT-2023-32271 | Ecological Momentary Assessment of Muscle Tension Dysphonia |
| ENT-2024-33112 | Assessment of usability and satisfaction with a take-home device presenting sound and body stimulation for back pain |
| FMCH-2019-28219 | Bupropion for the Prevention of Postpartum Smoking Relapse |
| FMCH-2022-30581 | Contingency Management as a Treatment for Opioid Use Disorder and Stimulant Use Disorder in a Primary Care Setting |
| FMCH-2022-31326 | Multi-level predictors of structural racism and discrimination and associations with health and well-being across the life course in diverse families |
| FMCH-2023-31990 | Understanding modifiable barriers to treatment adherence in youth with type 2 diabetes to inform intervention development |
| FMCH-2023-32305 | Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children |
| FMCH-2023-32980 | Strengths-based, Culturally Responsive, Body Positive Approaches to Adolescent Nutrition-related Health |
| FMCH-2024-32723 | Developing and pilot testing an intervention to reduce household shisha smoke exposure within Somali homes |
| FMCH-2024-32739 | Gender Identity Measurement In Early School Aged Children |
| FMCH-2024-33260 | A Qualitative Study of Cannabis Use Among Transgender and Gender Diverse People Across the Cancer Care Continuum |
| FMCH-2024-33441 | Exploring the Effects of Comorbidities on Diabetes Care in Hmong Patients in Minnesota |
| FSCN-2023-31797 | A dual-arm randomized cross-over trial to assess wHether ORganic grass-fed cow MEat increases Levels of SCFAs and SCFA-producing bacteria, and reduces inflammatory type 2 diabetes biomarkers including A1c |
| FVCTS-2022-J2J-MC-JZLH | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
| FVCTS-2023-SGNDV-001-KN-D74 | An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater) |
| FVCV-2020-ORION4 | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease |
| FVCV-2023-HERMES | Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. |
| FVCV-2023-LUXDXTRENDS | LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study |
| FVCV-2024-ARTEMIS | ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in
patients with acute myocardial infarction |
| FVCV-2024-BALANCEDHF | A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function |
| FVCV-2024-SIMPLAAFY | WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Alternative Post-Implant Monotherapy |
| FVFT-2024-ALASKA | On Wrist Sensing Technologies Study |
| FVMMCORC-2020-S1703 | RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER |
| FVMMCORC-2022-A011801 | The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib |
| FVMMCORC-2022-EA2176 | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients |
| FVMMCORC-2022-EA5182 | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) |
| FVMMCORC-2022-NRG-BN011 | NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination
Therapy Versus Standard Temozolomide in Patients with Methylated MGMT
Promoter Glioblastoma |
| FVMMCORC-2022-NRG-BR007RG | A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer |
| FVMMCORC-2022-NRG-GI004 | Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer |
| FVMMCORC-2022-NRG-GY019 | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole
Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous
Carcinoma of the Ovary or Peritoneum |
| FVMMCORC-2022-NSABP-C-14 | CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease |
| FVMMCORC-2022-S1706 | A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer |
| FVMMCORC-2022-WF1901 | Internet-delivered Management of Pain Among Cancer Treatment Survivors |
| FVMMCORC-2023-NRG-CC010 | A PHASE III TRIAL OF THE IMPACT OF SENTINEL LYMPH NODE
MAPPING ON PATIENT REPORTED LOWER EXTREMITY LIMB
DYSFUNCTION IN ENDOMETRIAL CANCER |
| FVMMCORC-2023-S1925 | S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and
Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in
Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic
Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” |
| FVMMCORC-2023-S2302 | Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer |
| FVMMCORC-2023-URCC16070 | Treatment of Refractory Nausea |
| FVMMCORC-2023-URCC21038 | Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in a Community Oncology Setting |
| FVMMCORC-2024-A012103 | OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy |
| FVMMCORC-2024-NRGGY028 | NRG-GY028: A PHASE IB AND RANDOMIZED PHASE II TRIAL OF
MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN
RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL
CANCER |
| FVMMCORC-2024-S2206 | S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus
Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint
Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal
Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer |
| FVMMCORC-2024-SGNDV005 | A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2 |
| FVMMCORC-2025-A021804 | A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma |
| FVMMCORC-2025-CAMBRIA-2 | CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
| FVMMCORC-2025-EAY191-A6 | FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial |
| FVMMCORC-2025-S2013 | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study |
| FVMMCORC-2025-TRITON | A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON). |
| FVMMCORC-2025-WF2304 | Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics |
| FVMNCCTN-2022-PORTFLUSH | A Prospective, Randomized Study To Evaluate The Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12 Weeks |
| GI-2018-27358 | SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) Trial |
| GI-2019-27691 | Biopsy Associated Microbiome |
| GI-2019-27850 | Automated, Endoscopic Mucosal Disease Activity Scoring for Ulcerative Colitis |
| GI-2019-28228 | Corrona Inflammatory Bowel Disease (IBD) Registry |
| GI-2021-29987 | Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the management of portal hypertension A 5-year longitudinal observational study of patients with cirrhosis undergoing TIPS placement |
| GI-2021-30033 | RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with inflammatory bowel disease: The OPTIMIZE Trial |
| GI-2022-30547 | A novel partial-enteral nutrition protocol to improve nutrition status of adult patients experiencing a Crohn's disease flare and starting new immunologic therapy |
| GI-2022-30940 | Compassionate use of domperidone for patients with gastrointestinal motility disorders. |
| GI-2022-31460 | Dietary optimization of microbiome recovery following fecal microbiota transplantation |
| GI-2022-31466 | Fecal biomarkers in discordant Clostridioides difficile lab testing |
| GI-2023-31858 | The women with inflammatory Bowel Disease and Motherhood: A Prospective Registry |
| GI-2023-32220 | CD4 T cell response to COVID vaccination |
| GI-2023-32303 | A Phase 1 Prospective Study of the Miromatrix External Liver Assist Product (miroliverELAP®) for Liver Support in Adults with Acute Liver Failure. |
| GI-2023-32481 | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) |
| GI-2023-32528 | Antigen-specific T cells and the gut microbiome in celiac disease |
| GI-2024-33127 | Standardized Microbiota Transplant Therapy in Crohn's Disease |
| GI-2024-33432 | The Useful Registry of Donors |
| GIM-2019-27913 | Identification and Management of Hepatitis C at an FQHC |
| HOT-2022-31276 | Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills after Cancer-Related Surgery |
| HOT-2022-31308 | Management of Anticoagulation around Delivery: a VENUS Prospective Cohort Study |
| HOT-2022-31518 | EFC17574: A Phase 3, single-arm, multicenter, multinational, open label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged >= 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX |
| HOT-2023-30373 | Effect of Kava on Anxiety and Stress in Cancer Survivors |
| HOT-2023-32170 | Characterizing the Logistic Toxicity of cancer treatment in non-English speaking population undergoing active cancer directed treatment |
| HOT-2023-32600 | Evaluation of the tumor microenvironment in myeloma lytic lesions and its impact on treatment |
| ICD-2024-33152 | Health's Early Roots & Origins (HERO) Study |
| ICD-2024-33463 | Measurement of task-evoked infant brain activity using fMRI |
| IDIM-2019-27395 | Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease |
| IDIM-2020-28516 | Investigation of Persistent HIV Immune Stimulation in Lymphoid Tissues During Therapy as a Cause of Sustained Immune Activation |
| IDIM-2022-31091 | A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole |
| IDIM-2022-31098 | Expanded Access IND Protocol: Use of Tecovirimat (TPOXX) for Treatment of Human Orthopoxvirus Infections |
| IDIM-2022-31268 | A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis |
| IDIM-2022-31448 | 018 / ACTIV: A Multicenter, Adaptive, Randomized, Controlled Trial Platform To Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections |
| IDIM-2022-31486 | Seasonal influenza vaccine high dose boosting in solid organ transplant recipients |
| IDIM-2023-31585 | Longitudinal assessment of the diversity and drug resistance of the gut microbiome before and after liver transplantation |
| IDIM-2023-31621 | A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species |
| IDIM-2023-31815 | CLINPRT-7: Intermediate Patient Population Expanded Access Protocol for MBP134 for Patients with Sudan Virus Disease (SVD) |
| IDIM-2023-32153 | A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1) |
| IDIM-2023-32285 | Zepto Lifes Proposal for Retrospective Convenience
Samples Collaboration with Dr. Youngs Team |
| IDIM-2023-32364 | Effectiveness of Screening and Decolonization of S. aureus to Prevent S. aureus Surgical Site Infections in Surgery Outpatients |
| IDIM-2023-32562 | A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) |
| IDIM-2024-32897 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION:
THE RESTORATIVE303 STUDY |
| IDIM-2024-32935 | A randomized, double-blind, placebo- controlled study of LMN-201 for prevention of C. difficile infection recurrence (RePreve) |
| IDIM-2024-33312 | A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection |
| IDIM-2024-33364 | Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients with Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia coli Pre-Transplant |
| IDIM-2024-33403 | CLINPRT-6: An Intermediate Patient Population Expanded Access Protocol for MBP091 for Patients with Marburg Virus Disease (MVD) |
| KIN-2022-31329 | teleABLE: Adapting a Behavioral Activation-Based Intervention to Reduce Post-Stroke Sedentary Behavior Using Telehealth (Formative Phase) |
| LMP-2022-29026 | ApheresUS Pilot Study |
| MED-2019-27772 | Outcomes in Acquired Hemophilia A |
| MED-2020-29410 | Adolescent and Parent Perspectives on Weight Management Approaches for Adolescents with Obesity |
| MED-2022-30228 | A feasibility study of topical cannabinoids for treatment of aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) in women with hormone receptor-positive breast cancer (CanAroma) |
| MED-2022-30316 | Time Restricted Eating as a Viable Alternative to Caloric Restriction for Treating Hyperglycemia in a Population with Type 2 (T2DM) diabetes |
| MED-2022-30904 | Single dose liposomal amphotericin for asymptomatic cryptococcal antigenemia |
| MED-2022-31096 | Development of novel screening methods for Cushing's disease |
| MED-2022-31407 | Predicting and preventing patient deterioration |
| MED-2023-32038 | Feasibility Study of Fasting Program for Individuals with T1DM |
| MED-2023-32321 | FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults with Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis (Aim 3) |
| MED-2024-32696 | Hypertension Identification using mobile Health Outreach ProjEct 2 (HI HOPE 2) |
| MED-2024-32816 | Bionic Pancreas in CFRD: A Randomized Trial of the Insulin-only Bionic Pancreas in Cystic Fibrosis Related Diabetes |
| MED-2024-32929 | Help Us Help U: Your Voice in Research |
| MED-2024-32954 | Non-Invasive Sleep and Circadian Rhythm Assessment Pre- and Post-surgery in Cushing Disease |
| MEDCHEM-2022-31071 | Cooked Meat and Prostate DNA Damage |
| MIDB-2022-31246 | Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention Outcome Measures |
| MNCCTN013 | Endocrine Therapy-Induced Alopecia Natural History Evaluation |
| MNCCTN027 | Topical cannabidiol (CBD) for the treatment of chemotherapy-induced peripheral neuropathy: a randomized placebo-controlled pilot trial |
| MNCCTN032 | Reishi Mushroom Extract for fatigue and/or arthralgias in patients with breast cancer on aromatase inhibitors: a randomized phase II MNCCTN trial |
| MNCCTN037 | Phase III Study of Ginseng for Cancer Related Fatigue |
| NEPH-2019-28024 | NEPTUNE: The Nephrotic Syndrome Study Network - RDCRN Protocol 6801 |
| NEPH-2019-28115 | APOL1 Long-term Kidney Transplantation Outcomes Network |
| NEPH-2022-30962 | Minnesota KPMP CKD and Resilient Diabetes Recruiting Site |
| NEPH-2023-32084 | MT2024-07:A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus (RESET-SLE) |
| NEPH-2023-32117 | A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy |
| NEPH-2023-32118 | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN). |
| NEPH-2024-32860 | The Women Kidney Program |
| NEPH-2024-33379 | Use of Artificial Intelligence to Improve Nephrology Fellow Education |
| NEUR-2019-28159 | Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery |
| NEUR-2019-28388 | Plasticity of motor systems in early stage Parkinson's disease |
| NEUR-2020-28530 | A Prospective, Long Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy |
| NEUR-2020-29420 | Transdiagnostic Cognitive Biomarkers |
| NEUR-2021-30029 | Minnesota Neurogenetics Repository |
| NEUR-2021-30334 | PRECISE |
| NEUR-2021-30478 | Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
| NEUR-2022-30942 | Natural History Study for DNA Repair Disorders |
| NEUR-2022-31003 | Neuroplasticity in REM Sleep Behavior Disorder |
| NEUR-2022-31174 | Defining Clinical Endpoints in LGMD |
| NEUR-2022-31334 | Defining Endpoints in Becker Muscular Dystrophy |
| NEUR-2022-31415 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (ribitol) in Patients with Limb Girdle Muscular Dystrophy 21 (LGMD21) |
| NEUR-2023-32286 | Multimodal profiling of response to pediatric Comprehensive Behavioral Intervention for Tics |
| NEUR-2023-32429 | Syn-Sleep Study |
| NEUR-2023-32484 | Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM sleep Behavior Disorder |
| NEUR-2024-32971 | Biorepository to Support ALS Research in Minnesota |
| NEUR-2024-33465 | ASSESS ALL ALS Study |
| NEUR-2024-33466 | PREVENT ALL ALS |
| NEURO-2020-28994 | FVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial |
| NEURO-2022-30954 | Feasibility of transcranial focused ultrasound to target brain tumor |
| NEURO-2022-31075 | Telefitting spinal cord Stimulation for Pain - The TSP Study |
| NEURO-2022-31385 | Extracranial Venous Narrowing in Headache and Dizziness |
| NEUROSURG-2021-29717 | Improving Spinal Cord Stimulation with ECAP |
| NEUROSURG-2024-33254 | Feasibility of Precision Functional Mapping for Pre-Surgical Planning |
| NSU-2022-30582 | Trigeminal Evoked Responses to Improve Rhizotomy |
| NSU-2023-28275 | Molecular profiling of neurosurgical and otolaryngological diseases |
| NSU-2024-33331 | Precision functional and structural mapping using DTI and rs-fMRI in hydrocephalus patients undergoing endoscopic third ventriculostomy |
| OBGYN-2020-29359 | iELEVATE |
| OBGYN-2022-31532 | The University of Minnesota Perinatal Health Repository |
| OBGYN-2023-32442 | Environmental influences on Child Health Outcomes
(ECHO) Cohort Data and Biospecimen Collection
Protocol |
| OPH-2022-30605 | Topical Ice-therapy for pain modulation during Intravitreal Injections: A prospective randomized control trial |
| OPH-2022-30876 | An Assessment of the Prevalence of Cannabis Use Among Ophthalmic Patients |
| OPH-2022-31305 | A Phase III, Multicenter, Randomized, Double Masked, Placebo-Controlled Study of the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa |
| OPH-2023-31727 | Treatment of limbal stem cell deficiency with Descemet's membrane corneal on-lay |
| OPH-2024-32782 | Investigating Losartan Effect on Glaucoma Filtration Surgery |
| OPH-2024-33337 | A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis |
| OPH-2024-33447 | Evaluating a novel 3-D printed double Maddox rod versus gold standard in the measurement of torsional strabismus |
| ORSU-2018-26821 | DegenPRO: A multicenter prospective registry for the management of degenerative spine disorders |
| ORSU-2018-27173 | A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface Structure on Progression of Fusion in XLIF® Surgery |
| ORSU-2020-29161 | Stability 2: ACL Reconstruction +/- Lateral Tenodesis with Patellar vs Quad Tendon (Protocol # PRO19020231) |
| ORSU-2022-31524 | Accuracy of Virtual versus Actual Trajectory in Pelvic Fixation Implant Placement Using Intra-Operative Cone Beam CT (O-arm) and 3D Navigation |
| ORSU-2022-31554 | Rod Unbending Force of Correction - Can We Predict How Much To Over-Bend? |
| ORSU-2023-31517 | Pelvic fixation and fusion during multilevel spinal surgery (PAULA) |
| ORTHOSURG-2024-33106 | A Randomized Comparative Cohort Study of the Use of Intra-articular Corticosteroid Injection Compared to Suprascapular Nerve Block for Treatment of Shoulder Pain |
| ORTHOSURG-2024-33151 | A Comparative Study of the Biologic Tuberoplasty and Subacromial Balloon Spacer in Treatment of Massive Irreparable Rotator Cuff Tears: Do they Reduce Bone-to-Bone Contact Between the Tuberosity and Acromion? |
| OT-2022-31410 | Describe how University of Minnesota occupational therapy doctorate students learn during onsite and telehealth clinical experience |
| OVNS-2019-28044 | Research Study of the Anatomy of Eye Muscles |
| PACCS-2020-23242 | Phase II Randomized, Intervention Versus Non-Intervention, Multi-center Study of the Effects of Thyroid Hormone (T3) on Safety/Tolerability and Oxygenation in Subjects with Acute Respiratory Distress Syndrome (ARDS) |
| PACCS-2021-30089 | R01HL153613: Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis |
| PACCS-2021-30269 | myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD patients in the home - a multi-center randomized controlled trial |
| PACCS-2021-30431 | Nintedanib Pharmacogenomics in Idiopathic Pulmonary Fibrosis (IPF) |
| PACCS-2022-30905 | One minute sit-to-stand test correlation with six-minute walk test and outcomes in fibrosing interstitial lung disease |
| PACCS-2022-31187 | RVN-001: A Phase 3, open-label, randomized, standard of care-controlled, parallel study arm study to demonstrate efficacy and safety of ARINA-1 in the prevention of bronchiolitis obliterans syndrome progression in participants with a bilateral lung transplant |
| PACCS-2022-31207 | The Lung Cell Study (TLC) |
| PACCS-2022-31232 | The Blood Study (TB Study) |
| PACCS-2022-31529 | Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF (STRONG-CF) |
| PACCS-2023-31589 | LTx READY CF 2: A Multi-Site RCT: Lung Transplant Resources for Education And Decision-making for Your CF 2 Study: A Multi-Site Randomized Controlled Clinical Trial |
| PACCS-2023-32123 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants |
| PACCS-2023-32158 | RESPIR-102: A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection |
| PACCS-2023-32172 | Implementing Patient-Reported Outcome Measures (PROMs) to Assess Disease Impact and Quality of Life in Sarcoidosis Patients |
| PACCS-2023-32267 | Molecular Characterization of Progressive Pulmonary Sarcoidosis |
| PACCS-2023-32411 | ABATE-IP-18: A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are Colonized with Nontuberculous Mycobacteria (The ABATE Study) |
| PACCS-2023-32418 | Cystic Fibrosis Lung Transplant Consortium (CFLTC) Airway Brushings in CLAD Study |
| PACCS-2023-32430 | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF) |
| PACCS-2023-32485 | A seamless, Phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations |
| PACCS-2024-32693 | COPDGene - Phase 4: GENETIC EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| PACCS-2024-32807 | Health Outcomes of Parents with Cystic Fibrosis (HOPe:CF) Aim 2 |
| PACCS-2024-32945 | A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of INBRX-101 in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema |
| PACCS-2024-33024 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF) |
| PACCS-2024-33081 | REACH-OB-23: A REsearch Study to Advance the CF THerapeutics Pipeline for People without Modulators |
| PACCS-2024-33147 | HUD - IBV Valve System, a Humanitarian Use Device for control of prolonged air leaks under HDE H060002 |
| PEDS-2017-25993 | Genetic and early life modifiers of NF1-related outcomes |
| PEDS-2017-26277 | Outcomes and Survivorship in Pediatric Germ Cell Tumors |
| PEDS-2018-25868 | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant |
| PEDS-2018-27007 | ALX-HPP-501: An Observational,Longitudinal Prospective, Long-term Registry of Patients with Hypophosphatasia |
| PEDS-2019-27671 | Integrating self-weighing at home to the clinical care of adolescents with obesity who are seeking weight loss treatment |
| PEDS-2019-27867 | A Multi-Center, Low lnterventional Study with a Retrospective Component in Participants with Late Onset Pompe Disease |
| PEDS-2019-27873 | A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fabry Disease |
| PEDS-2019-28147 | PediAtric ReseArch of Drugs, Immunoparalysis and Genetics during MODS (PARADIGM) |
| PEDS-2019-28223 | Retrospective evaluation of factors influencing outcomes in transcatheter pulmonary valve outcomes |
| PEDS-2019-28291 | Seizure disorder in cardiofaciocutaneous syndrome: Clinical characteristics, therapeutics and impact on quality of life |
| PEDS-2019-28341 | Clinical and Basic Investigations into Congenital Disorders of Glycosylation |
| PEDS-2020-28560 | An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose PR001A in Infants with Type 2 Gaucher Disease |
| PEDS-2020-28571 | A Descriptive Study of Child and Family Variables Related to Obesity in Autism Spectrum Disorder |
| PEDS-2020-28586 | Prospective validation of a venous thrombosis risk assessment model in critically ill children from the CHAT Registry |
| PEDS-2020-28763 | Long-term outcomes of interventional aortic valvuloplasty performed in the first year of life, a multicenter retrospective cohort study through the Pediatric Cardiac Care Consortium (PCCC) |
| PEDS-2020-28768 | CureGN: Cure Glomerulonephropathy Network
Version 2.0 |
| PEDS-2020-28885 | A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 1 to 24 Months with Type 1 (Infantile) and Type 2a (Late Infantile) GM1 Gangliosidosis |
| PEDS-2020-29065 | Genetic Risk for Obesity as a Predictor for Topiramate Response |
| PEDS-2020-29172 | BEGIN-OB-19: A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN) |
| PEDS-2020-29347 | Improving Diagnosis and Treatment in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
| PEDS-2021-29482 | ALL Childhood Heroes Assessment of Movement and Performance: Cardiac Fitness, Neuropathy and Lung Function Among Survivors of Leukemia Through Exercise (FLASHLITE) |
| PEDS-2021-29532 | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases |
| PEDS-2021-29635 | Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies |
| PEDS-2021-29649 | Pregnancy and Postpartum Support Programs for Women in Prison: Maternal and Neonatal Outcomes |
| PEDS-2021-29656 | Neurodevelopmental outcomes in preterm infants with jaundice |
| PEDS-2021-29697 | Self-Weighing for Weight Management in Adolescents Seeking Obesity Treatment: A Randomized Pilot |
| PEDS-2021-29744 | Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK OFF JSpA) |
| PEDS-2021-29769 | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK) |
| PEDS-2021-29784 | Lifestyle Counseling and Medication for Adolescent Weight Management |
| PEDS-2021-29785 | Phentermine/Topiramate in Adolescents with Type 2 Diabetes and Obesity |
| PEDS-2021-29867 | Genomics of nephrotic syndrome and nephrotic syndrome/FSGS relapse after kidney transplantation |
| PEDS-2021-29897 | Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) |
| PEDS-2021-29939 | SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics,;and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children: Aged 6 to 17 Years with Congenital Adrenal Hyperplasia |
| PEDS-2021-30034 | A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) Patients |
| PEDS-2021-30049 | Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program (LC-FAOD DMP) |
| PEDS-2021-30179 | The association between COVID-19 vaccination and activation of pediatric tubulointerstitial/glomerular diseases |
| PEDS-2021-30298 | Genetic, genomic, and biomarker studies of membranous nephropathy in kids. |
| PEDS-2021-30494 | Personalized immunomodulation in pediatric sepsis-induced MODS (PRECISE) |
| PEDS-2022-29947 | Maternal probiotic supplementation for improved neurodevelopmental outcomes in infants of diabetic mothers (IDMs) |
| PEDS-2022-30439 | Unexplored pathways: the impact of abnormal glycosylation on thehypothalamic-pituitary-adrenal and -gonadal axes and bone health in patients with congenitaldisorders of glycosylation |
| PEDS-2022-30545 | Evaluation of the best educational method to teach novice operators how to measure the optic nerve sheath diameter in pediatric patients. |
| PEDS-2022-30684 | A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis |
| PEDS-2022-30696 | A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis |
| PEDS-2022-30750 | Use of blood gene expression profile and donor-derived cell-free DNA to monitor response to treatment after biopsy-proven acute rejection in pediatric kidney transplant recipients (Omnigraf Study) |
| PEDS-2022-30889 | Building Resilience in Adrenoleukodystrophy with Imaging and Neuropsychology (BRAIN) |
| PEDS-2022-30932 | An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome |
| PEDS-2022-30981 | Lisdexamfetamine for the Treatment of Severe Obesity in Children Aged 6 to 12 Years |
| PEDS-2022-30991 | Pulse Oximetry and Skin Pigmentation |
| PEDS-2022-31314 | Optimizing Health Services for Youth Experiencing Homelessness |
| PEDS-2022-31347 | An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety,and Pharmacokinetics of FP-001 42 mg Controlled Release in Patients with Central (Gonadotropin-Dependent) Precocious Puberty |
| PEDS-2023-31392 | Global Registry For Novel Therapies In Rare Bone & Endocrine Conditions |
| PEDS-2023-31559 | A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age; mRNA-1647-P104 |
| PEDS-2023-31716 | Registry Study of Childhood Cancer in Minnesota |
| PEDS-2023-31753 | Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy |
| PEDS-2023-31817 | Pilot of standardized cognitive behavioral therapy for young adults with sickle cell disease |
| PEDS-2023-31913 | Pathogen Genomics Center of Excellence: Prospective Surveillance of Respiratory Pathogens and Antimicrobial Resistance in Diverse Regional Populations (MINNE-LOVE-2) |
| PEDS-2023-31967 | A 12-WEEK, PHASE 2 OPEN-LABEL, SEQUENTIAL DOSE COHORT STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CRN04894 TREATMENT IN PARTICIPANTS WITH CONGENITAL ADRENAL HYPERPLASIA |
| PEDS-2023-31978 | Establishing patient derived xenografts for MPNST |
| PEDS-2023-32113 | A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin) (SkybriGHt) |
| PEDS-2023-32129 | A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin (SkyPASS) |
| PEDS-2023-32163 | A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Moderate to
Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy |
| PEDS-2023-32176 | Assessing the Dose and Time to Administration of Antibiotics in the Pediatric Emergency Department: A Quality Improvement Investigation Comparing Pyxis vs Pharmacy Administered Medications |
| PEDS-2023-32268 | A Phase 1 Pharmacokinetic and Safety Assessment of Oral Letermovir in Infants with Symptomatic Congenital Cytomegalovirus Disease |
| PEDS-2023-32381 | Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis (Study M23-732) |
| PEDS-2023-32510 | SKoIRM-MN: Screening Kinesiology of Infants at Risk of Movement disorders |
| PEDS-2023-32559 | Causal Modeling of Ecological Momentary Assessment and Wearable Data in Youth |
| PEDS-2024-32318 | A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, efficacy, and pharmacokinetics of budesonide extended-release tablets administered once daily in pediatic subjects aged 5 to 17 years with active, mild to moderative ulcerative colitis |
| PEDS-2024-32632 | A Multicenter Multinational Observational Study of Children with
Hypochondroplasia |
| PEDS-2024-32633 | A Multicenter Observational Study to Characterize Growth in Children with Idiopathic Short Stature |
| PEDS-2024-33020 | A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients with Sanfilippo Syndrome Type A (MPS IIIA). |
| PEDS-2024-33262 | A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) |
| PEDS-2024-33352 | Understanding Patient and Family Perspectives on Racial and Ethnic Disparities in Pediatric Care: A Survey to Promote Health Equity |
| PEDS-2024-33452 | Masonic Institute for the Developing Brain Positive Behavior Program |
| PEDS-2024-33576 | Oral health related quality of life of adolescents and adults living with HIV in the Greater Accra Region, Ghana. |
| PHARM-2021-31875 | Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease |
| PHARM-2023-32102 | Pharmacogenomics to guide antidepressant selection in adolescents |
| PHARM-2024-32398 | Go4PGx Locker Research Repository |
| PMR-2021-29617 | Imaging of the Skin and Surrounding Tissue of Axillary Web Syndrome (AWS) and Lymphedema |
| PMR-2021-30243 | Autonomic and Vascular Mechanisms of Cardiovascular Risk in Women with Post-traumatic Stress-Disorder (PTSD) |
| PMR-2021-30275 | Minnesota Regional SCIMS |
| PMR-2021-30498 | A Clinical Trial of Cognitive Multisensory Rehabilitation for Sensory and Motor Recovery in Adults with Spinal Cord Injury |
| PMR-2022-30887 | Role of Spasticity in Predicting Functional Recovery following Spinal Cord Injury |
| PMR-2022-30925 | Biomechanical Mechanisms of Soft Tissue Deformation during the Volleyball Spike |
| PMR-2022-31565 | Remotely Delivered Cognitive Multisensory Rehabilitation for Sensory and Motor Recovery after Spinal Cord Injury |
| PMR-2023-31801 | Ecological Momentary Assessments to investigate causal relationships of factors that influence chronic pain |
| PMR-2024-33285 | Financial Assistance Module - Phase II |
| PSYCH-2016-24287 | Focus in NeuroDevelopment (FIND) Network: A Statewide Network for Research in Neurodevelopment |
| PSYCH-2018-27965 | Outpatient Experiences in Mental Health Treatment |
| PSYCH-2019-27591 | Enhanced Spatial Targeting in ECT Utilizing Focally Electrically-administered Seizure Therapy (FEAST) |
| PSYCH-2019-27785 | Individual Differences in Opioid use disorder |
| PSYCH-2019-28084 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
| PSYCH-2019-28336 | Neural mechanisms of early visual dysfunction in psychosis |
| PSYCH-2020-28579 | Examining the Association between Social Cognitive Deficits and Suicidal Ideation in Eating Disorders |
| PSYCH-2020-28582 | Consortium of Psychosis Research Recruitment |
| PSYCH-2020-28714 | Mechanistic Circuit Markers of Transcranial Magnetic Stimulation Outcomes in Pharmacoresistant Depression |
| PSYCH-2020-28827 | Neural Bases of Disgust Conditioning in Anorexia Nervosa |
| PSYCH-2020-28854 | Neurobiological and Psychological Maintenance Mechanisms Associated with Anticipatory Rewards in Bulimia Nervosa |
| PSYCH-2020-28866 | State Representation in Early Psychosis |
| PSYCH-2020-29302 | Thinking and Reasoning – Online Testing (TAROT) |
| PSYCH-2020-29337 | Cortical Inhibitory Biomarkers of Acute Suicidal States in Adolescents |
| PSYCH-2020-29400 | Neurofeedback and Neural Plasticity of Self-Processing and Affect Regulation Circuits in Suicide Attempting Adolescents |
| PSYCH-2021-30083 | OCD DBS Registry |
| PSYCH-2021-30129 | Creativity Camp Study |
| PSYCH-2021-30305 | Visual Perception in Visual Snow Syndrome |
| PSYCH-2022-30611 | The connection between Anxiety and Gastrointestinal Sensations in Individuals with an Eating Disorder |
| PSYCH-2022-30688 | Remote State Representation in Early Psychosis (Rem-STEP) |
| PSYCH-2022-30727 | NEA Research Lab |
| PSYCH-2022-30910 | tDCS and cognitive training as a neurodevelopmental intervention in FASD |
| PSYCH-2022-31484 | TMS x Neureka |
| PSYCH-2023-31270 | COMPARE: Expanding first-line options for depression and matching
treatments to patients: hatha yoga vs. behavioral therapy |
| PSYCH-2023-31626 | Technology Assisted Treatment for Binge Eating Disorder |
| PSYCH-2023-31860 | Addressing Appetitive Traits to Promote Weight Management in Children who Overeat (Family, Responsibility, Education, Support, and Health for food Responsiveness (FRESH-FR)) |
| PSYCH-2023-31861 | A Phase III, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of COMP360 in participants with treatment-resistant depression |
| PSYCH-2023-31936 | EPI-MINN: Targeting Cognition and Motivation in Coordinated Specialty Care for Early Psychosis: A National Comparison Study |
| PSYCH-2023-31938 | Brain Training for Substance Use Disorders |
| PSYCH-2023-32060 | TMS x DPX |
| PSYCH-2023-32232 | Psychology and Health |
| PSYCH-2023-32292 | Modeling Tic Change during Behavior Therapy for Tics |
| PSYCH-2023-32328 | Transcranial Magnetic Stimulation to Augment Exposure and Response Prevention for Pediatric OCD |
| PSYCH-2023-32483 | Movie fMRI for Substance Use Disorders |
| PSYCH-2023-32527 | Interoception, Heartrate Variability, and Eating Disorder Pathology in Real-Time (iHEART) Study |
| PSYCH-2024-31551 | tDCS and cognitive training for restrictive eating disorders |
| PSYCH-2024-32572 | Computational Modeling of Tic Change Trajectories in Tourette Syndrome |
| PSYCH-2024-32713 | Optimizing transcranial magnetic stimulation for stimulant use disorder |
| PSYCH-2024-32722 | Investigating the Effects of VNS on Central Autonomic Network and Interoception |
| PSYCH-2024-33119 | Validation of Flexible, Wearable Sensors to Detect and Monitor Tics |
| PSYCH-2024-33146 | Identification of Optimal Stimulation Contacts through Cognitive Testing in Deep Brain Stimulation for Psychiatric Indications |
| PSYCH-2024-33283 | Responding and Adapting to Barriers Before Integrative Translation (Rabbit) |
| PSYCH-2024-33300 | St. Louis Park Interventional Psychiatry Surgical Treatment Options Registry |
| PSYCH-2024-33344 | Older twin imaging pilot study |
| PSYCH-2024-33445 | Precision Longitudinal Brain-Behavior Mechanisms of Adolescent Executive Function: An Open Science MIDB Dataset |
| PSYCH-2025-33599 | Ethical Perspectives in Psychiatry |
| PSYCHOL-2017-33777 | Dynamic Effects in Peripheral Auditory Processing |
| PSYCHOL-2023-31867 | Auditory Perception in Mild Cognitive Impairment |
| PSYCHOL-2024-33195 | Effect of mild cognitive impairment on cortical processing of speech |
| PSYCHOL-2025-33680 | Neural Correlates of Goal Prioritization and Conscientiousness |
| PT-2018-27097 | Autonomic regulation of blood pressure in premature and early menopausal women |
| PT-2021-29864 | Vasomotor symptoms of menopause and cardiovascular disease: What is the link? |
| PT-2022-30683 | Asymmetries in motor control and their impact on functional independence |
| PT-2022-30735 | Diaphragmatic Breathing Exercises for post-COVID-19 Diaphragmatic Dysfunction (DD) |
| PT-2022-31097 | Effect of sensory perturbations on motor control |
| PT-2023-31814 | D2D: Menopause perspectives and beliefs in the community |
| PT-2024-32330 | Efficacy Verification in Early Diagnosis and Management of Lymphedema through Home Body Water Analyzer |
| PT-2024-32769 | Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function |
| RAD-2019-27687 | The Neuronal Underpinnings of Non-invasive Laminar fMRI |
| RAD-2022-30567 | Neurological Condition/Therapy Product Surveillance Registry (PSR) Platform Base |
| RAD-2022-30907 | ROWAN: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphereTM followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphereTM Alone For Hepatocellular Carcinoma (HCC). |
| RAD-2022-31045 | Vulnerability and Resiliency in the Aging Adult Brain Connectome (AABC) |
| RAD-2022-31520 | Neural Pathways of Applied Reflexology |
| RAD-2023-32046 | PULMONARY EMBOLISM - THROMBUS REMOVAL WITH CATHETER-DIRECTED THERAPY: THE PE-TRACT TRIAL
|
| RAD-2024-33399 | Individualized Mechanisms of Neural Plasticity and Response to Interventions in Neonates |
| RHEUM-2021-29914 | CONQUER Protocol Number 001: COllaborative, National QUality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (CONQUER) |
| RHEUM-2023-31961 | A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis |
| SLP-2022-30630 | Neural and Behavioral Markers of the Temporal Dynamics of Language Planning and Phonological Working Memory Processes in Persons Who Stutter |
| SLP-2022-30685 | Cochlear Implantation in Children with Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial |
| SLP-2023-30009 | Evaluation of an Explicit Approach to Teach Grammatical Forms to Children with Language Impairment |
| SLP-2023-31730 | Can spectral power and coherence reflect the integrity of the efferent cerebellar cortical pathway in cerebellar mutism syndrome? |
| SLP-2023-32065 | Developing Cancer Prevention Capacity through Community Health Workers |
| SON-2021-29969 | COCOA |
| SON-2021-30005 | Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training in MCI (The ACT Trial) |
| SON-2022-31447 | Intermittent Pneumatic Compression with and without Exercise to Improve Functioning in Peripheral Artery Disease: The INTERCEDE TRIAL |
| SON-2024-32760 | Health Beliefs and Behaviors of Lung Cancer Screening in Chinese Americans |
| SPH-2021-29712 | Dissecting the role of acetaldehyde in oral carcinogenesis |
| SPH-2022-31233 | Maternal Stress, Human Milk Composition, and Neurodevelopmental and Feeding Outcomes |
| SPH-2023-31237 | Assessing and understanding the impacts of experiencing racism in adolescence on cardiovascular disease risk markers in Twin Cities-based young adults |
| SPH-2023-31998 | Using Natural Language Processing to determine long term functional outcomes of Stroke patients |
| SPH-2023-32350 | mGlide-Care: A mHealth Partnership with caregivers to improve HTN management in patients with cognitive impairment |
| SPH-2024-33223 | Electronic Nicotine Delivery Systems (ENDS) Use and Access in Florida's Tobacco Regulatory Environment |
| SURG-2017-26057 | A Randomized Trial of Intra-Portal Alone Versus Intra- and Extra- Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis |
| SURG-2018-26636 | Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis |
| SURG-2019-27532 | Perspectives of HIV D+/R+ Transplant Recipients and Candidates |
| SURG-2021-29574 | Pilot Study to Correlate Ultrasound with Computer Tomography Measurements of Sarcopenia in Patients Undergoing Evaluation for Advanced Heart Failure Therapies |
| SURG-2021-30061 | University of Minnesota Critical Care Pilot Biobase |
| SURG-2021-30108 | Liver Collection Study |
| SURG-2022-30801 | Lung Transplant Clinical Center to Improve Surgical Outcomes |
| SURG-2022-30909 | Multiplexed ion beam imaging analysis of archived transbronchial biopsy specimens from lung transplant recipients |
| SURG-2022-31001 | Save the Bottoms!!!: Assessing the Gay Male Experience with Anal Cancer Prevention Strategies |
| SURG-2022-31309 | A 12-month, randomized, open-label, phase IIA study evaluating the safety and efficacy of siplizumab in combination with belatacept and MMF compared to standard of care immunosuppression in de novo renal transplant recipients (ASCEND). |
| SURG-2023-29833 | An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal Microbiota Transplantation In Patients Undergoing Colon Resection |
| SURG-2023-31213 | Research Evaluating Vagal Excitation and Anatomical Links |
| SURG-2023-31622 | CANADIAN-AUSTRALASIAN RANDOMISED TRIAL OF SCREENING KIDNEY TRANSPLANT CANDIDATES FOR CORONARY ARTERY DISEASE |
| SURG-2023-31628 | High-Resolution Anoscopy Registry |
| SURG-2023-31789 | BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation |
| SURG-2023-31841 | Surgical Site Infections (SSI) and the Microbiome: Understanding the Pathogenesis of SSI |
| SURG-2023-31889 | Proteomics of Post-Operative Complications in Patients undergoing CABG |
| SURG-2023-32068 | Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols |
| SURG-2023-32109 | OCS Heart Perfusion (OHP-II) Registry |
| SURG-2023-32349 | ltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females with Obstetric Injury (DigniFI) |
| SURG-2024-27972 | New Patient-Centered Metric for Transplant Report Cards; Aim 1 |
| SURG-2024-32767 | Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes |
| SURG-2024-33179 | OCS Liver Perfusion (OLP-II) Registry |
| SURG-2024-33321 | An Open-Label, Pilot Clinical Trial To Test The Efficacy Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection |
| URO-2021-29535 | Stratifying Patient Immune Endotypes in Sepsis (SPIES Study) |
| URO-2023-31695 | A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG- unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease |
| URO-2023-31989 | Immune Modulation Associations With Urinary tract Infection In People With Neurogenic Bladder. |
| URO-2023-32133 | Prophylactic Antibiotic Use to Prevent Urinary Tract Infection Following Radical Cystectomy and Urinary Diversion: Randomized Clinical Trial |
| URO-2023-32134 | Ostomy Simulation for Patient Education Prior to Urologic Bowel Diversion Surgeries |
| URO-2023-32437 | Comparison of motor and sensory thresholds for sacral neuromodulation |
| URO-2024-33637 | Support for Transgender and Non-Binary Individuals Seeking Vaginoplasty (STRIVE) Study |
| URO-2025-33695 | Bladder Management Patient Reported Outcomes for Young Adults with Spina Bifida |
| VETMD-2020-28606 | Histological assessment of osteochondritis dissecans specimens |
| VETMD-2020-28867 | Histological assessment of osteochondritis dissecans biopsies |
| VETMD-2022-30178 | Magnetic Resonance Imaging of Osteonecrosis of the Femoral Head |